C. Zanetta

发表

Stem cell transplantation for amyotrophic lateral sclerosis: therapeutic potential and perspectives on clinical translation

N. Bresolin, G. Comi, S. Corti, 2014, Cellular and Molecular Life Sciences.

Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis model

S. Salani, F. Rizzo, N. Bresolin, 2013, Human molecular genetics.

Pluripotent stem cell-based models of spinal muscular atrophy

S. Salani, S. Corti, F. Magri, 2015, Molecular and Cellular Neuroscience.

Impact of immunotherapies on COVID-19 outcomes in multiple sclerosis patients

M. Filippi, M. Rocca, C. Zanetta, 2022, Expert review of clinical immunology.

Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports

M. Filippi, L. Moiola, C. Zanetta, 2021, Neurological Sciences.

Direct reprogramming of human astrocytes into neural stem cells and neurons

S. Salani, C. Donadoni, F. Rizzo, 2012, Experimental cell research.

Antisense Oligonucleotide Therapy for the Treatment of C9ORF72 ALS/FTD Diseases

N. Bresolin, G. Comi, S. Corti, 2014, Molecular Neurobiology.

Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials.

N. Bresolin, G. Comi, S. Corti, 2014, Clinical therapeutics.

Therapeutic applications of the cell-penetrating HIV-1 Tat peptide.

S. Corti, A. Ramirez, M. Nizzardo, 2015, Drug Discovery Today.

Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy

N. Bresolin, G. Comi, S. Corti, 2013, Cellular and Molecular Life Sciences.

BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset

P. Gallo, F. Rinaldi, S. Ruggero, 2016, Journal of Neuroimmunology.

Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype.

S. Salani, F. Rizzo, N. Bresolin, 2014, Clinical therapeutics.

Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case–control study

V. Martinelli, P. Rancoita, M. Rocca, 2023, Journal of Neurology.

Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature

M. Filippi, L. Moiola, G. Liberatore, 2019, Journal of the Neurological Sciences.

Molecular, genetic and stem cell-mediated therapeutic strategies for spinal muscular atrophy (SMA)

N. Bresolin, G. Comi, S. Corti, 2014, Journal of cellular and molecular medicine.

Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing–remitting multiple sclerosis patients: a monocentric longitudinal observational study

V. Martinelli, M. Rocca, L. Moiola, 2023, Journal of Neurology.

Early Predictors of 9‐Year Disability in Pediatric Multiple Sclerosis

M. Filippi, M. Rocca, V. Martinelli, 2021, Annals of neurology.

Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy

N. Bresolin, G. Comi, S. Corti, 2013, Cellular and Molecular Life Sciences.

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.

M. Filippi, L. Moiola, A. Nozzolillo, 2021 .

Stem cell transplantation for amyotrophic lateral sclerosis: therapeutic potential and perspectives on clinical translation

N. Bresolin, G. Comi, S. Corti, 2014, Cellular and Molecular Life Sciences.

The wide spectrum of clinical phenotypes of spinal muscular atrophy with respiratory distress type 1: A systematic review

S. Corti, G. Riboldi, F. Magri, 2014, Journal of the Neurological Sciences.

Rehabilitative of COVID-19 patients with acute lower extremity Ischemia and amputation.

E. Houdayer, J. Abutalebi, S. Iannaccone, 2020, Journal of Rehabilitation Medicine.

Antisense Oligonucleotide Therapy for the Treatment of C9ORF72 ALS/FTD Diseases

N. Bresolin, G. Comi, S. Corti, 2014, Molecular Neurobiology.

Therapeutic applications of the cell-penetrating HIV-1 Tat peptide.

S. Corti, A. Ramirez, M. Nizzardo, 2015, Drug discovery today.

Ocrelizumab extended‐interval dosing in multiple sclerosis during SARS‐CoV‐2 pandemic: a real‐world experience

M. Rocca, L. Moiola, A. Nozzolillo, 2023, European journal of neurology.

Perspectives on Neuromyelitis Optica Spectrum Disorders, the Narrative Medicine contribution to care

M. Trojano, P. Iaffaldano, C. Chisari, 2023, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.

Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy

M. Rocca, C. Zanetta, L. Ferré, 2024, Frontiers in neurology.